Market Place
Sourcing Support
VIVUS & UpScriptHealth Launch ChooseQ.online for Weight Mgmt
30 Oct 2024 //
GLOBENEWSWIRE
Vivus Shares Significant Regulatory Update on QSYMIA®
28 Oct 2024 //
#N/A
VIVUS Announces Label Update for QSYMIA®
23 Oct 2024 //
GLOBENEWSWIRE
Vivus Commercializes QSIVA In Nordic Countries And Poland
07 Oct 2024 //
GLOBENEWSWIRE
VIVUS Launches Telehealth `Engage` With UpScriptHealth
22 Apr 2024 //
GLOBENEWSWIRE
Vivus` Biologic Pancreaze (pancrelipase) Receives Approval in the U.S.
28 Feb 2024 //
FDA
VIVUS Provides Update on Pipeline and Program Milestones
08 Jan 2024 //
GLOBENEWSWIRE
New Data Demonstrate that QSYMIA, the Leading Weight-Management Medication
28 Nov 2023 //
GLOBENEWSWIRE
VIVUS in Combination with a Digital Lifestyle Intervention Leads to Weight Loss
17 May 2023 //
GLOBENEWSWIRE
VIVUS Announces Key Management Updates to Support Global Expansion Strategy
10 Jan 2023 //
GLOBENEWSWIRE
ICER reaffirms Qsymia as most cost-effective obesity treatment in final report
31 Aug 2022 //
ENDPTS
FDA Approves Qsymia for Treating Teens With Obesity
29 Jun 2022 //
MEDSCAPE
Petros Partners with Global Contract Manufacturer for STENDRA`s production
24 Jan 2022 //
PRNEWSWIRE
VIVUS Completes Solicitation for In-Court Reorganization Plan to IEH Biopharma
07 Jul 2020 //
GLOBENEWSWIRE
VIVUS up 8% premarket on positive Qsymia effect in binge-eating disorder
19 Nov 2019 //
SEEKING ALPHA
Fighting obesity by attacking both food intake and energy burn
29 Jun 2019 //
FIERCE BIOTECH
In another misstep for Vivus, FDA`s promo police ding misleading Qsymia webpage
07 Jun 2019 //
FIERCE PHARMA
OPDP Issues Second Untitled Letter of 2019
30 May 2019 //
RAPS
Novo backs up M&A pledge by tapping deal-minded board chair
23 Mar 2018 //
FIERCE PHARMA
Alnylam`s Givosiran Gets Breakthrough Therapy Status by FDA
01 Jun 2017 //
NASDAQ
Gainers & Losers Of Mar.9: CBAY, IMMU, TGTX, NSPR, TNDM
09 Mar 2017 //
NASDAQ
Drugmakers Turn Cheap Generics Into Expensive Pills
31 Oct 2016 //
WALL STREET
Post-Endo pact, will Vivus go it alone on U.S. Stendra marketing--and should it?
05 Aug 2016 //
FIERCE PHARMA
Takeda dumps weight loss med Contrave, leaving Orexigen in the lurch
16 Mar 2016 //
FIERCE PHARMA MARKETING
Hoping Vivus and Orexigen can finally kick-start their obesity meds?
29 Feb 2016 //
FIERCE PHARMA MARKETING
Takeda`s U.K unit brings sales force in-house to boost efforts in oncology, IBD
21 Jan 2016 //
FIERCE PHARMA MARKETING
More formulary exclusion are on their way as smaller PBMs get in the action
02 Dec 2015 //
FIERCE PHARMA
Are Takeda`s 900 Contrave reps worth it? Maybe not, analyst says
09 Nov 2015 //
FIERCE PHARMA MARKETING
Vivus counts $25M in Q3 sales, $300M in debt
05 Nov 2015 //
FIERCE PHARMA
Investors cheer as Arena forces out CEO and cofounder
06 Oct 2015 //
FIERCE PHARMA
Icahn casts his eye on Vivus with tender offer for convertible notes
09 Sep 2015 //
FIERCE PHARMA
Flailing Vivus halves hard-hit Qsymia sales force as revenue lags
31 Jul 2015 //
FIERCE PHARMA
Brutal honesty in drug marketing? For obesity meds, it`s key to avoiding the `magic pill` trap
09 Jun 2015 //
FIERCE PHARMA MARKETING
Eisai predicts long-awaited operating profit rise for fiscal 2015
15 May 2015 //
FIERCE PHARMA
VIVUS (VVUS) to Trim U.S. Salesforce By a Third
03 Apr 2015 //
BIOSPACE
Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money?
02 Apr 2015 //
PHARMALOT
FDA Provides Generic Approval Roadmap for 38 Drugs, Including Vertex`s Kaldeco
11 Mar 2015 //
RAPS
Surprise: Obesity Med Contrave Might Help CV Outcomes. Too Bad Orexigen Blabbed It
05 Mar 2015 //
FIERCE PHARMA
Activists Ready to Fight for Ariad CEO`s Ouster: CNBC
13 Feb 2015 //
FIERCE PHARMA
Novo Nordisk Puts 500 Saxenda Reps on U.S. Streets, Aiming for $1B in Weight-Loss Sales
26 Jan 2015 //
FIERCE PHARMA
Endo ends Stendra marketing pact, leaving Vivus in the lurch
05 Jan 2015 //
FIERCE PHARMA MARKETING
Endo International Kills Deals with Auxilium Pharma and Acerus
01 Jan 2015 //
BIOSPACE
